Mergers & Acquisitions Mergers & Acquisitions

Pharmaceutical-sector 'killer acquisitions' to get EU-funded antitrust study

By Natalie McNelis
  • 17 Aug 2021 07:39
  • 17 Aug 2021 07:39
“Killer acquisitions” in the pharmaceutical industry are set to undergo a new round of scrutiny with the EU’s announcement of a public tender for a formal study of the topic.

The EU merger-control watchdog is already sensitive to the threat of big companies snapping up innovative competitors, only to subsequently “kill” drug research

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News